‘Universal’ access for MDR-TB limited without the involvement of the private sector. Go to Publication You Might Also Like Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. August 30, 2019 Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. July 11, 2012 Spontaneous resolution of diffuse alveolar septal amyloidosis. July 3, 2001 Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres August 30, 2019 Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. March 2, 2015
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. August 30, 2019
Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. July 11, 2012
Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres August 30, 2019
Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. March 2, 2015